Statistics from Altmetric.com
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
This section features synopses of pertinent practical publications that appear in Pathology journals in the respective sub-specialties. The summaries are mere guidelines and personal opinions of the two authors. The articles selected are diverse but occasionally reflect the authors' bias and are from the more widely read pathology journals. It is not intended to be an assiduous search of every publication in every Pathology journal, but more of a general indication of some of the monthly highlights through the eyes of the authors.
Hopefully, these snippets will provide the reader with enough to glean some facts and tips, as well as encourage them to read the entire article if necessary.
British Journal of Haematology
Bacher U, Kohlmann A, Haferlach T. Current status of gene expression profiling in the diagnosis and management of acute leukaemia. Br J Haematol 2009;145:555–68.
The French-American-British (FAB) classification groups leukaemias according to their morphological appearance and was refined by cytogenetic analysis by the World Health Organization (WHO). However there can be great variation in outcome between leukaemias of the same subtype. Gene expression profiling is a powerful tool that has validated the FAB and WHO classifications of acute myeloid leukaemia. In addition, this technology risk stratifies patients with the same leukaemia, may be used to tailor treatments to individual patients and may identify potential new targets for treatment. Gene expression profiling will be introduced into clinical practice. This review provides a grasp of its progress so far, and the necessary directions for future development.
Wheatley K, Brookes CL, Howman AJ, et al. Prognostic factor analysis of the survival of elderly patients with AML in the MRC AML11 and LRF AML14 trials. Br J Haematol 2009;145:598–605.
Acute myeloid leukaemia (AML) carries a poor prognosis in patients over 60 years of age, whether they are treated with intensive …
Competing interests None.
Provenance and peer review Not commissioned; not externally peer reviewed.